The role of epigenetics in colorectal cancer

References

• Butler EN, Chawla N, Lund J, et al. Patterns of colorectal cancer care in the United States and Canada: a systematic review. J Natl Cancer Inst Monogr 2013;2013(46):13-35
   Google Scholar
• Altobelli E, Lattanzi A, Paduano R, et al. Colorectal cancer prevention in Europe: Burden of disease and status of screening programs. Prev Med 2014;62C:132-41
   Google Scholar
• Chawla N, Butler EN, Lund J, et al. Patterns of colorectal cancer care in Europe, Australia, and New Zealand. J Natl Cancer Inst Monogr 2013;2013(46):36-61
   Google Scholar
• Wilkes G, Hartshorn K. Clinical update: colon, rectal, and anal cancers. Semin Oncol Nurs 2012;28(4):e1-e22
   Google Scholar
• Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol 2011;2011:792362
   PubMedGoogle Scholar
• Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers 2013;5(2):676-713
   PubMedGoogle Scholar
• Zoratto F, Rossi L, Verrico M, et al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. Tumor Biol 2014; In press
   Google Scholar
• Coppedè F. Epigenetic biomarkers of colorectal cancer: focus on DNA methylation. Cancer Lett 2014;342(2):238-47
   PubMed Web of Science ®Google Scholar
• Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3(4):253-66
   PubMed Web of Science ®Google Scholar
• Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int 2011;2011:902674
   PubMedGoogle Scholar
• Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007;104(47):18654-9
   PubMed Web of Science ®Google Scholar
• Yagi K, Akagi K, Hayashi H, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 2010;16(1):21-33
   PubMed Web of Science ®Google Scholar
• Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012;22(2):271-82
   PubMed Web of Science ®Google Scholar
• Al-Sohaily S, Biankin A, Leong R, et al. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol 2012;27(9):1423-31
   PubMed Web of Science ®Google Scholar
• Sakai E, Ohata K, Chiba H, et al. Methylation epigenotypes and genetic features in colorectal laterally spreading tumours. Int J Cancer 2014; In press
   Google Scholar
• Coppedè F, Lopomo A, Spisni R, Migliore L. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol 2014;20(4):943-56
   PubMed Web of Science ®Google Scholar
• Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13(7):484-92
   PubMed Web of Science ®Google Scholar
• Ballestar E, Wolffe AP. Methyl-CpG-binding proteins. Targeting specific gene repression. Eur J Biochem 2001;268(1):1-6
   PubMedGoogle Scholar
• Luger K, Mäder AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389(6648):251-60
   PubMed Web of Science ®Google Scholar
• Berger SL. The complex language of chromatin regulation during transcription. Nature 2007;447(7143):407-12
   PubMed Web of Science ®Google Scholar
• Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005;6(11):838-49
   PubMed Web of Science ®Google Scholar
• Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J 2011;278(10):1598-609
   PubMed Web of Science ®Google Scholar
• Moazed D. Small RNAs in transcriptional gene silencing and genome defence. Nature 2009;457(7228):413-20
   PubMed Web of Science ®Google Scholar
• Saxena A, Carninci P. Long non-coding RNA modifies chromatin: epigenetic silencing by long non-coding RNAs. Bioessays 2011;33(11):830-9
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301(5895):89-92
   PubMed Web of Science ®Google Scholar
• Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8(12):686-700
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96(15):8681-6
   PubMed Web of Science ®Google Scholar
• Karpinski P, Walter M, Szmida E, et al. Intermediate- and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and -zero) in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013;22(2):201-8
   PubMed Web of Science ®Google Scholar
• Sakai E, Nakajima A, Kaneda A. Accumulation of aberrant DNA methylation during colorectal cancer development. World J Gastroenterol 2014;20(4):978-87
   PubMed Web of Science ®Google Scholar
• Issa JP. Colon cancer: it’s CIN or CIMP. Clin Cancer Res 2008;14(19):5939-40
   Google Scholar
• Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012;107(9):1315-29
   PubMed Web of Science ®Google Scholar
• Thiel A, Ristimäki A. Toward a molecular classification of colorectal cancer: the role of BRAF. Front Oncol 2013;3:281
   PubMedGoogle Scholar
• Coppedè F, Migheli F, Lopomo A, et al. Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism. Epigenetics 2014;9(4):621-33
   PubMed Web of Science ®Google Scholar
• Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14(8):16365-85
   PubMed Web of Science ®Google Scholar
• Guerrero S, Casanova I, Farré L, et al. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000;60(23):6750-6
   Web of Science ®Google Scholar
• Minoo P. Toward a Molecular Classification of Colorectal Cancer: the Role of MGMT. Front Oncol 2013;3:266
   PubMedGoogle Scholar
• Jass JR, Baker K, Zlobec I, et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ’fusion’ pathway to colorectal cancer. Histopathology 2006;49(2):121-31
   Google Scholar
• Iacopetta B, Russo A, Bazan V, et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 2006;17(5):842-7
   Google Scholar
• Lambert R, Tanaka S. Laterally spreading tumors in the colon and rectum. Eur J Gastroenterol Hepatol 2012;24(10):1123-11234
   PubMedGoogle Scholar
• Moon BS, Jeong WJ, Park J, et al. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling. J Natl Cancer Inst 2014;106(2):djt373
   PubMedGoogle Scholar
• Gazzoli I, Loda M, Garber J, et al. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002;62(14):3925-8
   Google Scholar
• Venkatachalam R, Ligtenberg MJ, Hoogerbrugge N, et al. The epigenetics of (hereditary) colorectal cancer. Cancer Genet Cytogenet 2010;203(1):1-6
   Google Scholar
• Hitchins MP. The role of epigenetics in Lynch syndrome. Fam Cancer 2013;12(2):189-205
   PubMed Web of Science ®Google Scholar
• Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Nat Genet 2009;41(1):112-17
   PubMed Web of Science ®Google Scholar
• Kaz AM, Wong CJ, Dzieciatkowski S, et al. Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics 2014;9(4):492-502
   PubMed Web of Science ®Google Scholar
• Ramírez N, Bandrés E, Navarro A, et al. Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions. Eur J Cancer 2008;44(17):2689-95
   Google Scholar
• Krakowczyk L, Strzelczyk JK, Adamek B, et al. Methylation of the MGMT and p16 genes in sporadic colorectal carcinoma and corresponding normal colonic mucosa. Med Sci Monit 2008;14(10):BR219-25
   PubMed Web of Science ®Google Scholar
• Rawson JB, Sun Z, Dicks E, et al. Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients. Nutr Cancer 2012;64(7):919-28
   PubMed Web of Science ®Google Scholar
• Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 2010;102(14):1012-22
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006;98(23):1731-8
   PubMed Web of Science ®Google Scholar
• Nishihara R, Morikawa T, Kuchiba A, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol 2013;178(1):84-100
   PubMed Web of Science ®Google Scholar
• Gay LJ, Arends MJ, Mitrou PN, et al. MLH1 promoter methylation, diet, and lifestyle factors in mismatch repair deficient colorectal cancer patients from EPIC-Norfolk. Nutr Cancer 2011;63(7):1000-10
   PubMed Web of Science ®Google Scholar
• Hughes LA, Simons CC, van den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One 2011;6(4):e18571
   PubMed Web of Science ®Google Scholar
• Wu AH, Siegmund KD, Long TI, et al. Hormone therapy, DNA methylation and colon cancer. Carcinogenesis 2010;31(6):1060-7
   PubMed Web of Science ®Google Scholar
• Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013;26(4):465-84
   PubMed Web of Science ®Google Scholar
• Reimers MS, Zeestraten EC, Kuppen PJ, et al. Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) 2013;1(3):166-83
   Google Scholar
• Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9(Suppl 5):S1-S32
   PubMed Web of Science ®Google Scholar
• Grützmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008;3(11):e3759
   Google Scholar
• Gyparaki MT, Basdra EK, Papavassiliou AG. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. J Mol Med (Berl) 2013;91(11):1249-56
   Google Scholar
• Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 2008;103(11):2862-70
   PubMed Web of Science ®Google Scholar
• Yang H, Xia BQ, Jiang B, et al. Diagnostic value of stool DNA testing for multiple markers of colorectal cancer and advanced adenoma: a meta-analysis. Can J Gastroenterol 2013;27(8):467-75
   Google Scholar
• Guo Q, Song Y, Zhang H, et al. Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients. Med Oncol 2013;30(4):695
   Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; In press
   Google Scholar
• Nilsson TK, Löf-Öhlin ZM, Sun XF. DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Int J Oncol 2013;42:127-33
   Google Scholar
• Xing X, Cai W, Shi H, et al. The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer 2013;108:2542-8
   Google Scholar
• Kohonen-Corish MR, Tseung J, Chan C, et al. K-RAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. Int J Cancer 2014;134(12):2820-8
   Google Scholar
• Jensen LH, Rasmussen AA, Byriel L, et al. Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study. Cell Oncol (Dordr) 2013;36(5):411-19
   PubMed Web of Science ®Google Scholar
• Bae JM, Kim JH, Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 2013;109(4):1004-12
   PubMed Web of Science ®Google Scholar
• Katoh H, Yamashita K, Waraya M, et al. Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer. Neoplasia 2012;14(7):559-71
   Google Scholar
• Yi JM, Dhir M, Van Neste L, et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 2011;17(6):1535-45
   PubMed Web of Science ®Google Scholar
• Baba Y, Nosho K, Shima K, et al. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology 2010;139(6):1855-64
   PubMed Web of Science ®Google Scholar
• Draht MX, Smits KM, Tournier B, et al. Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients. Mol Oncol 2014; in press
   Google Scholar
• Dallol A, Al-Maghrabi J, Buhmeida A, et al. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2012;21(11):2069-75
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Moutinho C, et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res 2013;19(8):2265-72
   PubMed Web of Science ®Google Scholar
• Ebert MP, Tänzer M, Balluff B, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med 2012;366(1):44-53
   PubMed Web of Science ®Google Scholar
• Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology 2012;143(6):1442-60
   PubMed Web of Science ®Google Scholar
• Gargalionis AN, Piperi C, Adamopoulos C, Papavassiliou AG. Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. Int J Biochem Cell Biol 2012;44(8):1276-89
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhan S, Tan W, et al. P300 binds to and acetylates MTA2 to promote colorectal cancer cells growth. Biochem Biophys Res Commun 2014;444(3):387-90
   Google Scholar
• Rönsch K, Jäger M, Schöpflin A, et al. Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer. Epigenetics 2011;6(5):610-22
   PubMed Web of Science ®Google Scholar
• Stypula-Cyrus Y, Damania D, Kunte DP, et al. HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One 2013;8(5):e64600
   PubMed Web of Science ®Google Scholar
• Nosho K, Shima K, Irahara N, et al. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2009;22(7):922-32
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Kondo T, Ma D, et al. Global histone modification of histone H3 in colorectal cancer and its precursor lesions. Hum Pathol 2012;43(6):834-42
   PubMedGoogle Scholar
• Tamagawa H, Oshima T, Numata M, et al. Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. Eur J Surg Oncol 2013;39(6):655-61
   Google Scholar
• Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009;10(10):697-708
   PubMed Web of Science ®Google Scholar
• Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007;39(2):237-42
   PubMed Web of Science ®Google Scholar
• Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 2013;73(10):2936-42
   PubMed Web of Science ®Google Scholar
• Jie D, Zhongmin Z, Guoqing L, et al. Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer. Dig Dis Sci 2013;58(6):1581-9
   PubMed Web of Science ®Google Scholar
• Gezer U, Ustek D, Yörüker EE, et al. Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumour Biol 2013;34(1):329-36
   Google Scholar
• Tamagawa H, Oshima T, Shiozawa M, et al. The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep 2012;27(3):637-42
   PubMed Web of Science ®Google Scholar
• Vaiopoulos AG, Athanasoula KC, Papavassiliou AG. Epigenetic modifications in colorectal cancer: Molecular insights and therapeutic challenges. Biochim Biophys Acta 2014;1842(7):971-80
   PubMed Web of Science ®Google Scholar
• Michael MZ, O’ Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1(12):882-91
   PubMed Web of Science ®Google Scholar
• Bonfrate L, Altomare DF, Di Lena M, et al. MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. J Gastrointestin Liver Dis 2013;22(3):311-20
   PubMed Web of Science ®Google Scholar
• PubMed database. Available from: www.ncbi.nlm.nih.gov/pubmed
   Google Scholar
• Aslam MI, Patel M, Singh B, et al. MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J Transl Med 2013;10:128
   Google Scholar
• Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27(15):2128-36
   PubMed Web of Science ®Google Scholar
• Lou X, Qi X, Zhang Y, et al. Decreased expression of microRNA-625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancer. J Surg Oncol 2013;108(4):230-5
   PubMed Web of Science ®Google Scholar
• Bojmar L, Karlsson E, Ellegård S, et al. The role of microRNA-200 in progression of human colorectal and breast cancer. PLoS One 2013;8(12):e84815
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou Y, Feng X, et al. Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer 2014;53(4):358-65
   PubMed Web of Science ®Google Scholar
• Slattery ML, Wolff E, Hoffman MD, et al. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer 2011;50(3):196-206
   PubMed Web of Science ®Google Scholar
• Mosakhani N, Sarhadi VK, Borze I, et al. MicroRNA profiling differentiates colorectal cancer according to K-RAS status. Genes Chromosomes Cancer 2012;51(1):1-9
   Google Scholar
• Nosho K, Igarashi H, Nojima M, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis 2014;35(4):776-83
   PubMed Web of Science ®Google Scholar
• Svoboda M, Slyskova J, Schneiderova M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis 2014; In press
   Google Scholar
• Qi P, Xu MD, Ni SJ, et al. Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. Mol Carcinog 2014; In press
   Google Scholar
• Xiang JF, Yin QF, Chen T, et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res 2014; In press
   Google Scholar
• Wang G, Li Z, Zhao Q, et al. LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. Oncol Rep 2014;31(4):1839-45
   PubMed Web of Science ®Google Scholar
• Xu MD, Qi P, Du X. Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application. Mod Pathol 2014; In press
   Google Scholar
• Zhou XJ, Dong ZG, Yang YM, et al. Limited diagnostic value of microRNAs for detecting colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev 2013;14(8):4699-704
   Google Scholar
• Diaz T, Tejero R, Moreno I, et al. Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J Surg Oncol 2014; In press
   Google Scholar
• Pichler M, Ress AL, Winter E, et al. MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. Br J Cancer 2014;110(6):1614-421
   PubMed Web of Science ®Google Scholar
• Xia X, Yang B, Zhai X, et al. Prognostic role of microRNA-21 in colorectal cancer: a meta-analysis. PLoS One 2013;8(11):e80426
   PubMed Web of Science ®Google Scholar
• Chen Q, Xia HW, Ge XJ, et al. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev 2013;14(12):7421-6
   PubMedGoogle Scholar